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ABSTRACT
We have attempted to characterize the changes occurring on the host side 
during the progression of human melanoma. To investigate the role of tumor 
microenvironment, we set up such an animal model, which was able to isolate the host 
related factors playing central role in metastasis formation. One of these ’factors’, 
CCL12, was consequently selected and its behavior was examined alongside its human 
homologue (CCL8). In our animal model, metastasis forming primary melanoma in 
the host exhibited increased level of CCL12 mRNA expression. In clinical samples, 
when examining the tumor and the host together, the cumulative (tumor and host) 
CCL8 expression was lower in the group in which human primary melanoma formed 
lung metastasis compared to non-metastatic primary tumors. We could not detect 
significant difference in CCL8 receptor (CCR1) expression between the two groups. 
Increased migration of the examined tumor cell lines was observed when CCL8 was 
applied as a chemoattractant. The tumor cells and their interactions can be influenced 
the expression of CCL8 by dermal fibroblasts, as a significant change in the metastatic 
microenvironment. Furthermore, we examined changes in miRNA profile resulted by 
CCL8 and miR146a appears to be a promising prognostic marker for following this 
process.
INTRODUCTION
Clinicians face the most difficult of treatment 
plans when it comes to metastatic melanoma. Surgical 
resection of the primary tumor and resection/treatment 
of the regional lymph nodes in stage II and resectable 
stage III melanoma could lead to a disease free status. The 
treatment of unresectable stage II, stage IV and recurrent 
melanoma is not quite as straightforward with numerous 
treatment options. The response rate to conventional 
chemotherapy (DTIC, Temozolomide) is only 10-15% 
with even lower occurrence of complete remission. 
Therefore the fact that melanoma is a highly immunogenic 
tumor raised high hopes for immune therapies. Most of 
these are immune checkpoint inhibitors, such as anti-
CTLA-4, anti-PD-1. The discovery and introduction of 
signal transduction inhibitors, BRAF inhibitors (for tumor 
harboring V600E mutation), MEK inhibitors targeting 
MEK1 and MEK2, both of which are downstream in 
the BRAF signal transduction pathway, multikinase 
inhibitors and KIT inhibitors have brought a revolutionary 
change in melanoma therapy. Although the response rate 
significantly increased, there was no dramatic change in 
overall survival, despite the expectations. It is therefore 
of utmost importance that we understand the mechanism 
of progression and metastasis formation of melanoma [1].
The basis of metastasis research is examining each 
step of the cascade of tumor progression. Stages in this 
process are separated into two aspects: tumor and host 
related factors, with the distinction between the two 
sometimes blurred. Interaction between tumor cells and 
their microenvironment does not only provide opportunity 
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for tumor growth, but can also lead to the selection of a 
metastatic population of tumor cells [2]. This interaction 
can form the metastatic niche, by providing an angiogenic 
phenotype [3], extracellular matrix rearrangements via 
production and storage of chemokines and growth factors 
[4, 5, 6], changes in migration potential [7], and will lead 
to tumor formation of the selected cells due to stromal 
cell activation [8]. The primary stromal components of 
importance are the fibroblasts, which are reprogrammed 
as tumor associated fibroblasts by tumor cells, and provide 
part of the molecular environment for the primary tumor 
[9]. Surprisingly, it is this environment that provides the 
premetastatic and metastatic niche at the sites of distant 
metastases and promotes colonization by the selected 
tumor cell clones [10, 11]. Several genes have been 
identified as participants in the activation of the metastatic 
cascade, however the complete spectrum of genes has yet 
to be revealed. [12, 13, 14].
Chemokines are small molecular weight proteins 
which can bind specific G protein coupled cell surface 
receptors [15]. They play a key role in many areas, 
such as migration, inflammation, immune response 
and tumor growth. The classification of chemokines is 
based on the pattern of the cysteine residue containing 
protein C terminus which can be divided into four major 
groups: CXC, CX3C, CC and C, where C is cysteine 
and X denotes any other amino acid. Functionally, there 
are homeostatic and inflammatory cytokines [15]. The 
nomenclature of cytokines is not uniform, special attention 
should therefore be paid to make sure that a certain 
human chemokine molecule is paired and examined 
with its correct, homologous mouse counterpart. [16]. 
Several members of the tumor-host system have been 
proven to take part in tumor progression, such as tumor 
growth, migration, angiogenesis and EMT [17, 18]. The 
metastatic cascade is the step by step process, which 
represents the route by which tumor cells can travel from 
the primary tumor through the blood and lymph systems 
[19]. The occurrence of metastases shows a certain 
pattern, indicating that it might not be a random set of 
events. Physiologically, chemokines are involved in the 
management of leukocyte migration and by a similar 
method they promote organ specific tumor metastasis 
formation. In the most studied, CXCR4/CXCL12 system, 
tumors overexpressing CXCR4 had high metastatic 
potential to CXCL12 expressing organs, i.e. mostly lymph 
nodes [20]. This correlation can be observed in multiple 
tumor types (eg. breast [21], colorectal [22], prostate [23] 
and melanoma [24] tumors). Likewise, clear correlation 
was shown between CCR7 expression and lymph node 
metastasis formation via lymphatic vessels in case of head 
and neck cancers, NSCLC and melanoma [25, 26]. Tumors 
showing de novo expression of CCR7 in a murine isograft 
system [27] (B16F10 melanoma bearing animals) showed 
lymph node metastases, whereas lung metastases were 
formed in the absence of CCR7 expression [28]. The same 
connection was demonstrated in human clinical samples. 
A similar relationship was observed between lymphogenic 
metastasis and CXCR3 expression. Namely, in a B16F10 
melanoma mouse model, the loss of CXCR3 expression 
was demonstrated to reduce the incidence of lymph node 
metastasis by 15% [29]. The importance of the chemokine 
system in melanoma metastasis formation is further 
supported by a study in which high levels of CCR9 in the 
primary tumor promoted metastasis formation in the small 
intestine [30], whereas increased CCR10 level induced the 
appearance of skin metastases [31]. The CC chemokine, 
CCL8 (MCP2) molecule was investigated during 
inflammatory response for its monocyte and T-lymphocyte 
attractant properties. The cell surface receptors of CCL8 
are CCR1, CCR2 and CCR5, all of which belong to the 
CC chemokine receptor family [32]. Examining the host-
derived factors affecting the behavior of human melanoma 
in our experimental models, we have demonstrated CCL8 
to have a regulatory role during melanoma progression. 
RESULTS
Single cell suspension of the human melanoma 
cell line, HT168M1 was orthotopically implanted into 
adult and newborn SCID mice simultaneously. There 
was primary tumor growth in both hosts, but metastases 
only formed in the newborn host. The experiment was 
terminated after 30 days and RNA isolated from the 
metastatic primary tumor (newborn host). The RNA 
expression pattern of the metastatic host was investigated 
by Agilent Mouse Oligo Microarray Platform containing 
20,000 genes. The stromal expression changes were 
compared with tissue derived from corresponding area of 
tumor implantation of healthy, age-matched controls. The 
nineteen genes showing the largest expression changes 
(Figure 1.) were then chosen and their expression further 
examined on samples from three genetically different 
human melanoma cell lines (HT168M1, WM983B, 
HT199) implanted into the same metastatic / non-
metastatic model. The species specificity of the primers 
for every examined gene was checked by using them on 
human and mouse tumor cell lines. This was necessary to 
ensure that the expression changes were strictly mouse-
derived stroma related, therefore only those primers giving 
clear products in the target species (mouse), but not in 
human, were validated. PCR products were identified by 
direct sequencing. Nine out of 19 genes were suitable to 
be used as host specific markers: Fam 187b, Lass5, DEAD 
box 60 polypeptide, Gm4262, CCL11, Pex2, Cathepsin L, 
CCL12 and Ninein. Total RNA was then isolated from 
the implanted in vitro cultures and in vivo subcutaneous 
primary tumors of all three melanoma cell lines, and the 
relative expression of target genes was determined by real 
time PCR. To assess the role of these genes in providing 
a microenvironment prone to select a more metastatically 
potent subset of cells, we compared the relative expression 
Oncotarget3www.impactjournals.com/oncotarget
pattern of these genes in the non-metastatic and metastatic 
version of each of the three melanoma cell lines growing 
in adult and newborn hosts respectively. 
The expression threshold used was 1.5 fold or higher 
in at least two cell lines. Five of the nine genes fulfilled 
these requirements, namely Fam 187b, Lass5, DEAD 
box 60 polypeptide, Cathepsin L and CCL12 (Figure 
2). Unfortunately, any PCR-based technique would 
struggle to differentiate between host and tumor-derived 
expression of genes due to their genetic identity (Figure 
3A). Therefore, human homologues of the five genes were 
analyzed in our human melanoma cell lines. There was 
only one gene, CCL12 and its human homologue CCL8, 
which was expressed by only one human melanoma cell 
line (WM983B, which was derived from a melanoma 
metastasis) and therefore was proved to be suitable for 
further analysis. An almost two-fold difference was 
observed in the relative expression level of CCL12 
between metastatic and non-metastatic model in all tested 
cell lines (Figure 3B). This result ‚nominated‘ this gene to 
operate in the selection of metastatic tumor cells. 
We then examined the expression of CCL8 in five, 
genetically different human melanoma cell lines (HT199, 
HT168M1, WM983A, A2058, WM983B) and found that 
it was expressed by only one of them (WM983B) (Figure 
3C). Additionally, we demonstrated CCL8 expression 
in in vitro cell cultures of human dermal fibroblasts and 
melanocytes (Figure 3D). In order to find out which cell 
types are the potential targets of CCL8, the presence of 
CCL8 sensitive chemokine receptors was analyzed in the 
tumorous and several normal constituents of the tumor-
host system. Specifically, we examined the expressions of 
CCR1, CCR2 and CCR5 (Figure 3E). Expression of CCR1 
was detected in HT199, HT168 and WM983A tumor cell 
lines. Only dermal fibroblasts expressed CCR1 from the 
host side. 
After identification of the chemokine/receptor 
pattern of both sides of the tumor-host system, our next 
step was to map its functional effects. First of all, the 
effect of CCL8 on dermal fibroblasts, melanocytes and 
CCR1-expressing tumor cell lines was examined, using 
MTT-test. The effect of CCL8 on viability was compared 
to untreated control, using two different concentrations 
of CCL8, after 12 hours of treatment. To determine the 
optimal concentration range of the treatment we tested the 
viability of HT168M1 human melanoma cells. Based on 
the viability test the applied concentration was 0.5-10 ng/
ml (Figure 4B).
Significant difference was observed in HT199 of the 
tumor cells lines and in dermal fibroblasts of host cells 
in both cases at the concentration of 500 pg/ml, which 
reduced viability (Figure 4). 
The effect of CCL8 on migration, one of the key 
steps of the metastatic cascade, was measured with 
xCELLigence-system on CIM (Cell Invasion Migration) 
plate, semiquantitatively. Based on the detection of 
impedance by microelectrodes, the migration activity 
of the untreated control culture was compared with that 
of the treated cells. CCL8 was applied in two different 
ways on cell cultures: either added directly to the culture 
or as a chemoattractant. In both cases the administered 
concentrations were 1 and 10 ng/ml. Analyses started 5 
hours after treatment following which data were collected 
every 5 minutes for a duration of 18 hours. A summary 
Figure 1: Gene sets from microarray experiment. Single cell suspension of HT168M1 human melanoma cell line was 
semiorthotopically implanted into newborn SCID mice. The RNA expression pattern of this, metastatic version of the primary tumor 
was investigated via Agilent Mouse Oligo Microarray Platform. The stromal expression changes were compared to healthy, age matched 
controls and the nineteen genes showing the largest expressional changes were selected for further validation.
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of the results is presented in the table inserted in Figure 
5C. According to our observations, the migration of tumor 
cells was inhibited by CCL8 when applied directly and 
it was increased when added as chemoattractant. On the 
other hand, CCL8 as a chemoattractant either did not 
alter the migration of non-tumor cells or inhibited them 
(fibroblasts in low concentration) (Figure 5). When 
applied directly, CCL8 inhibited migration of both 
melanocytes and fibroblasts, while in lower concentration 
it significantly increased migration activity of fibroblasts. 
 Since the expression pattern of CCL8 was 
identified in the melanoma cell lines and non-tumoral cells 
(fibroblasts, melanocyte, keratinocyte) as well as human 
metastatic and non-metastatic melanoma samples in our 
metastatic animal model, we raised the question whether 
there was any correlation between chemokine expression 
and metastasis formation of human primary melanomas. 
Human surgical primary melanoma samples were 
divided into two groups: non-metastatic (NM) primary 
tumor - patients with no metastasis detected during a 
follow-up period of five years and metastatic (M) primary 
tumor - patients developing metastasis within five years. 
Data were retrospectively collected to include sex, age, 
tumor phenotype (pigmentation), tumor site, histological 
type, Clark level and Breslow thickness (Table 1A). 
Patients of the metastatic group had distant organ 
metastases (single or multiple) in the lung, liver, brain, 
bones, skin and lymph nodes (Table 1B). Total RNA was 
then isolated and the CCL8 expression determined in each 
sample, qualitatively in the first instance. Subsequently, 
the relative quantitative expression of CCL8 was also 
measured by real time PCR, comparing the CCL8 
Figure 2: Validation of microarray data. Three different human melanoma cell lines (HT199, HT168M1, WM983B) were 
semiorthotopically implanted at the same time into newborn (metastatic version) and adult (non-metastatic version) SCID mice. Lung 
metastases were detected only in the newborn host. Nine out of the previously selected 19 genes were suitable for host specific PCR. Their 
relative expression was measured in xenotransplanted metastatic and non-metastatic animal models. In every case, changes in expression 
of the target gene in the host of the metastatic and non-metastatic version of the primary tumor were compared with the expression level of 
the beta microglobulin housekeeping gene. The results were displayed as the ratio of expression levels in the two hosts, with the changes 
considered significant if the ratio was higher than 1.5-fold.
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Table 1: Clinical characteristics of the patient groups
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expression level with human beta actin expression 
(relative CCL8 expression). A total of 57 clinical primary 
melanoma samples were analyzed and no statistical 
difference was found between the metastatic and non-
metastatic group. Metastatic primary tumor samples were 
then further divided into 6 subgroups (patients with lung, 
liver, skin, bone, brain and lymph node metastases) based 
on the target organ of the metastases. Because of patients 
with multiple metastases in different locations the number 
of samples proved to be sufficient for our study only when 
we examined primary tumors forming lung metastases. 
When re-analyzing the data considering this subgroup, 
we found a significant difference between non-metastatic 
primary human melanoma and primary melanoma with 
lung metastases, the latter group expressing lower levels 
of CCL8 (Figure 6A). 
The expression of the CCL8 receptor, CCR1, was 
analyzed on the same samples, but no difference was 
observable between the analyzed non-metastatic primary 
human melanoma and primary melanoma with lung 
metastases groups (Figure 6B). 
It was not possible to separately examine CCL8 
mRNA expression of the stromal components in our 
surgical samples, therefore we used immunohistochemistry 
Figure 3: Qualitative and quantitative expression of CCL12 and CCL8. A. The qualitative CCL12 pattern showed that the host 
specific PCR was appropriate to discriminate between the implanted human melanoma cell line and the experimental tumor samples. B. 
Three human melanoma cell lines (HT199, WM983B, HT168M1) were implanted into newborn and adult SCID mice. A more than 1.5 fold 
change of CCL12 relative expression was detected between the primary subcutaneous tumor from the newborn (metastatic model) and adult 
(non-metastatic model) animals at RNA level. Data presented are mean values ± SD. C. CCL8 expression was investigated in six different 
human melanoma cell lines and was detected in only one of them (WM983B). D. The expression of CCL8 (human homologue of CCL12) 
was demonstrated in non-tumoral (dermal fibroblast, melanocyte) cells. The positive control was the ubiquitously CCL8 expressing K562 
leukemia cell line. E. The expression of CCL8 receptors (CCR1, CCR2 and CCR5) was analyzed in normal cells (dermal fibroblasts, 
melanocytes, keratinocytes) and tumor cell lines (HT199, A2058, WM983A, WM983B, HT168). CCR1 expression was only detected in 
fibroblasts and three different melanoma cell lines (HT199, HT168, WM983A).
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Figure 4: Effect of CCL8 on cell viability. The effect of CCL8 on cell viability was detected in the presence of two different 
concentrations (500 pg/ml and 1 ng/ml) of human recombinant CCL8 and was compared to untreated control, after 12 hours of treatment. 
The viability changes were measured by MTT test, where absorbance was detected on 570 nm proportionate to the number of living cells. 
Every tumor cell line and fibroblasts carried the CCL8 receptor, CCR1. Significant differences were observed in HT199 (tumor cell line) 
and dermal fibroblasts (host cell) at the concentration of 500 pg/ml, where viability was reduced in both cases. Data presented are mean 
values ± SD of absorbance obtained from 18 parallel samples in one representative experiment. *p < 0.005. B. Concentration range of 
CCL8 treatment on HT168 cell line
Figure 5: Effect of CCL8 on migration. A. Cells were treated with recombinant human CCL8, added directly to the cells in two 
different concentrations. Graphs represent the migration activity of cells 5 hours after treatment related to18 hours of data collection. In 
case of melanocytes the control line and the line of 10 ng/ul runs together. B. CCL8 was applied as a chemoattractant in two different 
concentrations, where cells migrated towards the chemokine source through a transwell membrane. Graphs represent the migration activity 
of cells 5 hours after treatment related to 18 hours of data collection. Data presented are cell index. *p < 0.005. C. Summarized results 
represent that directly added CCL8 inhibited tumor cell migration while as a chemoattractant it increased cell motility. The migration of 
non-tumor cells was either not altered, or was inhibited by CCL8 as a chemoattractant (fibroblasts in low concentration). 
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to reveal the localization and expression of CCL8. 
Heterogeneous expression of this protein was detected 
primarily in the stromal cells, and in the tumor as well, 
though to a lesser extent (Figure 6C). Systemic appearance 
of CCL8 in the serum of patients with melanoma was 
analyzed by ELISA kit, with recombinant CCL8 used to 
set the standard curve. During measurement, because of 
the detection limit, CCL8 concentrations lower than 60 pg/
ml were considered to be zero. Altogether, 36 serum (17 
metastatic and 19 non-metastatic) samples of patients with 
melanoma were analyzed and CCL8 protein concentration 
was higher than 60 pg/ml in 15(7 metastatic and 8 non-
metastatic) of the analyzed serum samples. The level of 
CCL8 protein was found to be greater in non-metastatic 
group of patients, however because of low sample number 
and broad range of standard deviation it did not prove to 
be statisically significant. (Figure 6D)
Our experimental animal model offered good 
possibility to examine tumor cell populations derived 
from different stages of the metastatic cascade, free of 
stromal components. Namely, cell cultures were created 
from metastatic and non-metastatic primary tumors, 
circulating tumor cells as well as lung metastases, and 
CCL8 expression was measured qualitatively. CCL8 
mRNA expression was detected in the lung metastases of 
the metastatic system (newborn model) and in circulating 
tumor cells of the non-metastatic system (adult model) 
(Figure 7) We could not prove the presence of CCL8 
Figure 6: CCL8 expression in human primary melanoma samples. Human melanoma samples were divided into two groups: 
non-metastatic primary tumor (NM - no metastases detected during the five year follow-up) and metastatic primary tumor (M - the patients 
developed metastases within five years). Patients of the metastatic group had distant organ metastases in the lung, liver, brain, bones, skin 
and lymph nodes. A. Relative expression of CCL8 in clinical samples was measured by real time PCR and significant differences were 
detected between non-metastatic and lung metastatic primary human melanomas, the latter expressing lower quantities of CCL8. B. There 
was no difference in CCR1 expression level between the two groups (lung metastatic vs. non-metastatic). C. Heterogeneous expression of 
CCL8 protein was detected in the human melanoma primary tumor samples by immunohistochemistry (magnification: 20x). D. Systemic 
appearance of CCL8 in serum of melanoma patients was analyzed by ELISA kit. Thirty-six samples were analyzed and CCL8 protein was 
detected. Differences found between metastatic and non-metastatic samples were not stasistically significant, because deviation of the datas.
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mRNA in cell culture derived from the primary tumor, 
although by analyzing the whole subcutaneous tumor 
tissue CCL8 was detectable by immunohistochemistry 
in a small group of tumor cells (Figure 7C). To further 
investigate the molecular cooperation between host and 
tumor, we treated human dermal fibroblasts with the 
supernatant of HT199 melanoma and K562 leukemia 
cell cultures as well as ’pure’ CCL8. Untreated cells and 
Figure 7: CCL8 expression of tumor cells from different stages of the metastatic cascade. A. Animal model of human 
melanoma progression. Primary tumors from adult and newborn hosts (SC t.: subcutaneously implanted tumor) were removed along with 
lung metastases (Lm), which were formed only in newborn mice. Primary cell cultures were created from all of the above tumors and from 
the circulating tumor cells (C tc.) of newborn and adult mice. B. CCL8 expression was qualitatively detected after mRNA isolation from 
the metastases of the metastatic system (newborn) and from the circulating tumor cells of the non-metastatic system (adult). C. CCL8 
expressing tumor cell clones were visualized at protein level in the metastatic (newborn) primary xenograft tumor by immunohistochemistry 
(magnification: 20x). 
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glucose solution were used as control. Dramatic increase 
of CCL8 expression was observed after melanoma and 
leukemia supernatant treatment, but in contrast ’pure’ 
CCL8 treatment terminated the continuous expression of 
CCL8 ( Figure 8).
The rapid effect of CCL8 on the gene expression 
of dermal fibroblasts suggests that microRNAs might be 
involved. In the two groups (CCL8 treated and control) 
the quantitative change of 800 human microRNAs 
was measured. We created a CCL8 specific microRNA 
pattern by including microRNAs showing fivefold or 
higher differences between the two groups. One of the 
microRNAs, miR146a, was also found in the middle 
range of our list (Figure 9), therefore playing role in the 
regulation of CCL8 in accordance with the literature 
[37]. miR146a level was measured in randomly selected 
five samples each of the metastatic and non-metastatic 
primary tumors of human melanoma patients, using 
nCounter assay. A statistically significant, higher miR146a 
expression level was found in the metastatic group 
(independent of metastasis localization) as compared with 
the non-metastatic group (Figure 10). 
DISCUSSION
The microenvironment, as one of the key 
components regulating tumor behavior, can take part in the 
destruction of small tumors, as well as sometimes support 
tumor growth and migration [34]. The combination 
of these two effects provides the selection pressure 
generating a specific tumor cell population: the metastatic 
tumor cell population. 
The metastatic phenotype (genotype) is the feature 
of tumor cells which are able to detach and leave the 
Figure 8: Simulation of host-tumor cooperation. Human dermal fibroblast cells were treated with HT199 melanoma and K562 
leukemia cell-free supernatants (to simulate the effect of secreted tumoral factors) and pure, recombinant human CCL8. We used untreated 
cells and samples treated with 0.01M glucose solution as controls. CCL8 relative expression was measured by real time PCR. A. Increase 
in CCL8 expression was observed after melanoma and leukemia supernatant treatment. B. In contrast, pure CCL8 treatment terminated the 
continuous expression of CCL8.
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Figure 9: CCL8 specific miRNA pattern. Human dermal fibroblasts were treated for 12 hours with human recombinant CCL8. 
MicroRNA quantitative profile was analyzed by nCounter miRNA Expression Assay Kit from NanoString. The changes were compared to 
miRNA levels measured in untreated control fibroblasts. MicroRNAs which showed fivefold or higher difference between the two groups 
were accepted, thus we created a CCL8 specific microRNA pattern. miR146a, which was localized in the middle range of our list, has 
already been described to participate in the regulation of CCL8, according to the literature [37].
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primary tumor, settle and form a new colony in distant 
organs [35]. Undoubtedly, this geno/phenotype develops 
as the result of a selection pressure, in which the host-
derived microenvironment plays a key role. We attempted 
to identify the molecular markers of this tumor-host 
interaction and examine their role in metastasis formation 
in our experimental animal model system. We have 
identified differences in the expression pattern of the 
examined genes in the metastatic and non-metastatic 
version of the same tumor type. However, it is yet to be 
decided if a specific pattern is homogenous throughout the 
entire tumor, or it is present only in a small subset of cells 
which are able to enter the metastatic cascade. If the latter 
is true, it is possible that beyond a certain threshold, a high 
enough quantity of this metastatically more potent subset 
can have a significant effect on the whole of the tumor, and 
can therefore be used as a prognostic marker of metastasis 
formation. CCL12 was one of the genes we identified as 
a possible host-related factor which might be involved in 
supporting a metastatic phenotype. This gene showed a 
more than 1.5-fold increased expression in the metastatic 
version of primary tumors, when compared to their non-
metastatic counterparts in all three of our xenograft animal 
models. We also showed that, with the exception of one 
(WM983B), all the examined human melanoma cell lines 
lacked expression of CCL8, the human homologue of 
CCL12. To identify the cells expressing CCL8 at the site 
of implantation, we analyzed the expression of this protein 
in dermal fibroblasts, melanocytes and keratinocytes. 
Among these cells, fibroblasts and melanocytes expressed 
the chemokine CCL8. However, it is not enough to simply 
identify the expression of these chemokines. One must 
Figure 10: miR146a expression in human primary melanoma. We investigated the quantitative expression of miR146a in 
randomly selected 5 metastatic and 5 non-metastatic primary melanomas. A significantly higher miR146a expression level was measured 
in the metastatic group (independent of the localization of the metastasis) than in the non-metastatic group. Data presented are mean values 
± SE.
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aim to discover their interactions by which they affect the 
complex process of metastasis formation. The effect of 
CCL8 is mediated by special chemokine receptors CCR1 
and CCR5. CCR1 expression was identified in fibroblasts 
and three of the five melanoma cell lines examined. None 
of the cell lines in our study showed CCR5 expression. 
Another aspect of the local effect of chemokines on cells 
is the way they affect viability and migration. The viability 
of one of the 3 studied melanoma cell lines and dermal 
fibroblasts was similarly influenced by CCL8 statistically, 
although this might not be a biologically relevant effect. 
In melanoma cell lines CCL8 increased the migration 
potential when added as a chemoattractant, while it did not 
alter the motility of host cells. In conclusion, CCL8 may 
enhance the ability of metastasis formation in melanomas 
as a chemoattractant. 
Our xenotransplantation animal model gave 
opportunity to study the behavior of tumor cells originating 
from various steps of the metastatic cascade. Namely, 
tumor cells from the primary tumor, circulating tumor cells 
and cells from lung metastasis were investigated in vitro. 
Our results showed that cell cultures from the primary 
tumor did not express the chemokine while cells isolated 
from the circulation and metastases both expressed CCL8. 
However, it is difficult to draw conclusion based on these 
findings, since circulating tumor cells represent a so called 
intermediate state, which merely carries the possibility and 
not a guarantee of metastasis formation. 
Since we revealed a quantitative expression 
difference of CCL12 between host cells of metastatic 
and non-metastatic xenograft primary tumors, we studied 
whether this expression difference could be detected 
in human clinical samples as well and whether it could 
possibly be used as prognostic marker to indicate tumor 
progression.
We analyzed clinical samples of patients suffering 
from melanoma We divided these samples into two 
groups: non-metastatic primary tumor (metastases did not 
occur during a five year follow-up) and metastatic primary 
tumor (metastases formed within five years). The quantity 
of CCL8 was measured by ELISA test in the serum of 
these patients. In some samples the chemokine was not 
present at all. Average CCL8 protein level was higher in 
the non-metastatic than in the metastatic group, but this 
difference was not statistically significant. Measuring 
the relative expression of CCL8 in human primary 
tumors, we did not find any distinction between the non-
metastatic and metastatic groups. However, comparison 
between the chemokine expression of primary tumors 
from patients with and without lung metastases showed 
significant difference. The expression of the receptor 
(CCR1) mediating the effects of CCL8 was similar in 
the two primary tumor groups. There was no difference 
in expression of the receptor (CCR1) mediating the 
effects of CCL8 between the two primary tumor groups. 
In order to decide which cell types could be the source 
of CCL8 production (stromal cells or tumor cells), 
immunohistochemistry was performed on clinical samples. 
We found that both stromal and tumor cells expressed 
CCL8, but the number of positive cells were higher 
in stroma. The small number of cells synthetizing this 
chemokine suggests a local rather than an overall effect.
We then examined the effect of two cell line 
supernatants (K562, HT168M1) on the CCL8 expression 
Figure 11: The hypothetical effect of CCL8 in host-tumor system. A. Soluble factors produced by tumor cells stimulate the 
CCL8 expression of dermal fibroblasts in the stroma. B. The increasing concentration of CCL8 and its chemoattractant ability results in an 
increased migration of tumor cells to the stroma. It also takes part in the selection of potentially CCL8 expressing tumor cells harboring 
metastatic potential. C. In this case the increasing CCL8 concentration can regulate its own expression in dermal fibroblasts. The change in 
miR146a expression (overexpressed in dermal fibroblasts in this case) serves as an appropriate marker for this process. 
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of dermal fibroblasts in vitro. Significant increase was 
found shortly after the treatment, while addition of pure 
CCL8 resulted in direct and complete reduction. This 
phenomenon could be due to miRNAs, which exhibit a 
regulatory function [36]. To reveal which miRNAs are 
responsible, the expressions of 800 miRNAs were studied 
in dermal fibroblasts, with expression level changes found 
in many of these miRNAs after CCL8 treatment. One of 
the candidate miRNAs we identified was miR146a, which 
has already been described as having a regulatory effect on 
CCL8 expression [37]. In our study, the expression level 
of this miRNA showed a significant difference between 
patients with metastatic and non-metastatic primary 
melanoma. 
Based on our results in xenotransplantation animal 
model and human clinical samples, we suggest that CCL8 
and its mouse homologue play a role in the metastatic 
cascade. The CCL8 expression of dermal fibroblasts was 
increased by soluble factors, produced by the tumor itself. 
CCL8 in return enhances the migration activity of tumor 
cells as chemoattractant. 
 According to our results, pure CCL8 treatment 
decreases the CCL8 expression of fibroblasts. It is a 
snapshot of the delicate balance of the stimulating effect 
of the tumor and the inhibition of CCL8 itself that we 
see during molecular studies. The role of numerous 
chemokines has been proven in the metastasis formation 
of human melanoma. Our studies support the role of a new 
member of metastasis associated chemokines, CCL8, in 
the formation of lung metastases. 
The apparent contradictions between our data from 
the animal model and clinical samples can be explained 
by a few facts. In the animal model we were only able 
to detect the relative chemokine expression of host 
cells with host (mouse) specific methods in contrast to 
clinical samples in which the whole cumulated (tumor 
and stroma) expression level was measured in order to 
validate the prognostic value. In conclusion we created 
a hypothetic process: factors of tumoral origin stimulate 
the chemokine expression of cells in their surroundings, 
mostly in fibroblasts and this chemokine functions as a 
chemoattractant molecule. As a consequence of the tumor-
host interaction, some of the tumor cells might be able to 
express CCL8. The local CCL8-rich environment could 
promote the selection of tumor cells with metastatic 
ability. The high CCL8 concentration inhibits the 
migration of tumor cells. In vitro studies showed that the 
exogenous CCL8 blocks the production of this protein 
in fibroblasts, thus if a CCL8 expressing population 
grows in the primary tumor, these cells could regulate the 
chemokine expression of tumor associated fibroblasts. Our 
data suggests that miR146a expression and CCL8 level are 
related. Therefore, miR146a could contribute to restoring 
the shifted balance, meaning that it is overexpressed 
in metastatic tumors. By contrast, in non-metastatic 
tumors low miR146a expression level is accompanied by 
relatively high CCL8 expression (Figure 11). However, 
this hypotesis should be supported by further analysis.
MATERIALS AND METHODS
Human xenograft model
Xenotransplantation was carried out by 
subcutaneous inoculation of freshly prepared cell 
suspension of human melanoma cell lines (HT199, 
HT168M1, WM983B, 5x106 cells/50 µl/animal) in 
the left hind leg of adult and newborn animals. On the 
30th day, the animals were sacrificed by bleeding under 
anesthesia. Primary in vitro cell cultures were formed 
from the primary tumor, circulating tumor cells and lung 
metastases of the same animal implanted as a newborn. 
Further, the primary tumor and circulating tumor cells 
from the adult animals were used to create cell cultures in 
a similar manner. This way the ’noise’ of communication 
with the microenvironment, such as skin, blood, lung, was 
excluded. Total RNA was isolated from the cultures.
This study was carried out in strict accordance 
with the recommendations and was approved by the 
Semmelweis University Regional and Institutional 
Committee of Science and Research Ethics (TUKEB 
permit number: 83/2009).
Tumor samples
Frozen samples of melanoma were stored in RNA 
later. Random sampling was applied throughout the 
experiments. Stratification of melanomas was based on 
the percentage of melanoma cells containing melanin. 
Melanomas were classified as amelanotic, moderately 
pigmented and strongly pigmented according to the 
literature [33]. The study was conducted in accordance 
with the Declaration of Helsinki and Good Clinical 
Practice, and with the approval of a Semmelweis 
University Regional and Institutional Committee of 
Science and Research Ethics (114/2012).
RNA samples
Total RNA was extracted from the original cell 
suspension and from the tissue samples (subcutaneous 
primary tumors and metastases) at the time of evaluation, 
using NucleoSpin RNAII total RNA isolation kit 
(MACHEREY-NAGEL GmbH, Düren) according to the 
manufacturer’s protocol.
The quality and integrity of total RNA were 
evaluated on 2100 Bio analyzer (Agilent Technologies, 
Palo Alto, CA) and the same samples were divided into 
individual aliquots for gene expression analysis on two 
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different microarray platforms and for the TaqMan Gene 
Expression Assay based real-time PCR analysis.
Agilent mouse oligo microarray analysis
The Agilent Mouse Oligo Microarray is comprised 
of 22,575 (60-mer) oligonucleotide probes representing 
20,000 mouse genes and transcripts in the mouse 
genome. Probe labeling and hybridization were carried 
out following the manufacturer‘s specified protocols. 
Briefly, amplification and labeling of 5 µg of total RNA 
were performed using Cy5 for healthy control skin sample 
RNA and Cy3 for newborn subcutaneous tumor sample 
RNA. Hybridization was performed for 16 hrs at 60°C 
and arrays were scanned on an Agilent DNA microarray 
scanner. Following the manufacturer’s protocol, Agilent’s 
Stabilization and Drying Solution (#5185-5979) was 
used to protect against the ozone-induced degradation of 
cyanine dyes on microarray slides during hybridization 
and processing steps. Images were analyzed and data were 
extracted, background was subtracted and normalized 
using the standard procedures of Agilent Feature 
Extraction Software A.7.5.1. Arrays were analyzed. 
Linear & LOWESS, the default normalization method 
in the Agilent Feature Extraction Software A.7.5.1, were 
applied for normalizing Agilent microarrays. The method 
performs a linear normalization across the entire range of 
data, followed by a non-linear normalization (LOWESS) 
to the linearized data set. 
cDNA synthesis
One μg of total RNA was reverse transcribed using 
oligo(dT)/random primer (2.5 μM) and MMLV reverse 
transcriptase (200 unit/μl, Finnzyme® Espoo, Finland). 
The reaction mixture was incubated at 37°C for 50 min, 
heated at 85°C for 10 min.
PCR
The primers were designed by ArrayDesigner 
software. DNA amplifications were performed using 
AmpliTaq Gold® 360 PCR Master Mix (Thermo Fisher 
Scientific Inc.) and Mastercycler gradient thermal cycler 
supplied by Eppendorf at 35 cycles of denaturation at 95 
oC for 1 min, primer annealing at 59 oC for 1 min, chain 
elongation at 72 oC for 2 min. After amplification 10 μl 
of PCR products were separated on 3% agarose gel and 
stained with ethidium bromide.
Quantitative PCR analysis
For quantitative measurement of the expressed 
genes (Fam 187b, Lass5, DEAD box 60 polypeptide, 
Gm4262, CCL11, Pex2, CathepsinL, mouse CCL12, 
Ninein, human CCL8, CCR1) q-PCR reactions were 
used Each 25 μl reaction mixture contained 12.5 μl of 2X 
 Table 2: Primer sets used
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iQ SYBR® Green Supermix (Bio-Rad), 0.5 μl of each 
primer for final concentration of 200 nM and 11.5 μl of 
the diluted cDNA. The used primers are presented in a 
separate table (Table 2). Cycling conditions comprised 
3 min of iTaq™ DNA polymerase activation at 95°C, 40 
cycles at 95°C for 30 sec, at 55°C for 30 sec and at 72°C 
for 1 min. Starting quantities were defined on the basis 
of standard fivefold dilution series (1X-625X) carried 
out with control cDNA of mouse B16 and human K562 
cell lines. Relative expression of the examined genes was 
determined by normalizing starting quantities to those of 
the housekeeping genes beta-2 microglobulin or beta actin 
from the same cDNA sample. 
Immunohistochemistry
Formalin fixed paraffin embedded sections of 
tumors were cut at a thickness of 2 μm. Sections were 
deparaffinated and to remove the melanin pigments we 
used potassium permanganate (KMnO4) with oxalic acid 
depigmentation protocol. Citrate buffer (pH 6) was used 
for microwave assisted antigen retrieval. After endogenous 
peroxidase quenching the sections were incubated 
overnight with mouse monoclonal CCL8 primary antibody 
in a dilution of 1:50 (Santa Cruz). Following extensive 
washings with PBS, sections were incubated for 1 h in 
the secondary biotinylated antibody, then the slides 
were developed by avidin-biotin peroxidase followed 
by incubation with diaminobenzidine or NovaRED™ 
Substrate (Vector Burlingame, CA). The negative control 
was prepared by omitting the primary antibody.
Cell lines
The A2058 melanoma cell line was provided by LA 
Liotta (NCI, Bethesda, MD). HT168 and HT168M1 lines 
are derivatives of A2058. HT199 was developed in the 1st 
Institute of Pathology and Experimental Cancer Research 
(Semmelweis University, Budapest, Hungary). WM983B 
and WM983A were gifts from M. Herlyn (Wistar Institute, 
Philadelphia, PA). Normal human melanocytes (C-12403), 
keratinocytes (C-12003) and dermal fibroblasts (C-12360) 
were derived from Promo Cell. Cells were maintained 
in RPMI 1640 medium supplemented with 5% fetal 
bovine serum (Sigma, St. Louis, MD) at 37°C in 5% CO
2
 
atmosphere.
Cell viability test
Cells (HT199, HT168, WM983A, fibroblast and 
melanocyte) were placed in 96-well tissue culture plates 
(6x103/well) in RPMI 1640 medium containing 5% FCS. 
After overnight incubation at 37°C, adherent cells were 
treated with CCL8 (R&D Systems, Minneapolis, MN, 
USA) (at final concentration of 500 pg/ml, 1 ng/ml) for 
12 hrs. At the end of the incubation period, a colorimetric 
assay (MTT test) was performed. Absorbance at 570 nm 
was measured with Bio-Tek Microplate Reader (Merck). 
Transmembrane migration assay
Human melanoma (HT168, WM983A), fibroblast 
and melanocyte cell migration was measured using a real 
time system (Roche xCELLigence). Cells were seeded at 
2x105/ml in 100 µl of RPMI 1640 medium. The first round 
of cells were treated with 1 and 10 ng/ml of exogenous 
CCL8 (R&D Systems) in the upper chamber with 8 µm 
pore size and the second round in the lower chamber as a 
chemoattractant. The control cells were treated with equal 
volume of PBS. Cell migration was monitored every 5 min 
by CIM plate 16 for a period of 0-23 hrs. 
ELISA
The human CCL8 ELISA kit (R&D Systems, 
according to the manufacturer’s protocol) was used 
to detect CCL8 in the serum of melanoma patients. 
Duplicated samples were analyzed using Bio-Tek 
Microplate Reader (Merck). Positive control wells were 
treated with recombinant CCL8 peptide.
miRNA assay
Digital quantification of microRNA was calculated 
using the nCounter System from nanoString Technologies.
Statistics
Results of quantitative PCR were analyzed with 
Stat Soft Statistica 11 software using unpaired t test. 
Cell viability and migration assays were analyzed using 
ANOVA and Scheffe post hoc test. Values of P ≤0.05 were 
considered significant.
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